Ivonescimab Achieves Statistically Significant Overall Survival in Phase III NSCLC Trial; Positive Phase II mCRC Data Also Reported
Summary
Summit Therapeutics announced groundbreaking Phase III overall survival data for ivonescimab in NSCLC, showing a 34% reduction in death risk, alongside positive Phase II results in mCRC, reinforcing the drug's potential across multiple cancer types.
Key Events
-
Groundbreaking Phase III Overall Survival Data in NSCLC
The HARMONi-6 trial showed ivonescimab plus chemotherapy reduced the risk of death by 34% (HR 0.66; p=0.0017) compared to tislelizumab plus chemotherapy in first-line squamous NSCLC. Median OS was 27.89 months vs. 23.69 months, with 24-month OS rates of 64.7% vs. 48.6%. This marks the first time a regimen has demonstrated a statistically significant OS benefit over anti-PD-(L)1 therapy plus chemotherapy in this setting.
-
Positive Phase II Data in Metastatic Colorectal Cancer
The AK112-206 trial in first-line mCRC demonstrated an objective response rate (ORR) of 70.8% and a disease control rate (DCR) of 100.0% across both ivonescimab dosing arms. The 20 mg/kg arm showed a 9-month duration of response of 79.1% and a 9-month progression-free survival rate of 76.1%, supporting continued development.
-
Consistent Safety Profile
Both trials reported acceptable and manageable safety profiles for ivonescimab, with no new safety signals observed. The safety data was consistent with previous studies, including those combining chemotherapy and anti-VEGF antibodies.
-
Results Published in The Lancet
The positive HARMONi-6 clinical trial results were simultaneously published in The Lancet, adding significant scientific validation and visibility to the findings.
Analysis
This filing reports highly significant positive clinical trial results for Summit Therapeutics' lead drug candidate, ivonescimab. The Phase III HARMONi-6 trial demonstrated a statistically significant overall survival benefit in first-line squamous non-small cell lung cancer (NSCLC), reducing the risk of death by 34% compared to a PD-1 inhibitor plus chemotherapy. This is a major breakthrough, as it's the first regimen to achieve such a benefit in this setting, validating ivonescimab's unique mechanism and significantly expanding its market potential. Additionally, encouraging Phase II data in metastatic colorectal cancer (mCRC) supports further development in another major indication. These results are critical for the company's future growth and de-risk its pipeline.
At the time of this filing, SMMT was trading at $18.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.6B. The 52-week trading range was $13.83 to $30.98. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.